FDC | BH.IMMUN&BIO | FDC/ BH.IMMUN&BIO |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.6 | -8.0 | - | View Chart |
P/BV | x | 3.7 | 1.6 | 237.8% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
FDC BH.IMMUN&BIO |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
FDC Mar-23 |
BH.IMMUN&BIO Mar-23 |
FDC/ BH.IMMUN&BIO |
5-Yr Chart Click to enlarge
|
||
High | Rs | 318 | 52 | 613.4% | |
Low | Rs | 229 | 21 | 1,117.8% | |
Sales per share (Unadj.) | Rs | 107.5 | 10.3 | 1,040.7% | |
Earnings per share (Unadj.) | Rs | 11.7 | -3.9 | -303.2% | |
Cash flow per share (Unadj.) | Rs | 14.0 | -3.8 | -368.5% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 119.5 | 20.4 | 584.8% | |
Shares outstanding (eoy) | m | 165.91 | 43.18 | 384.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.5 | 3.5 | 72.7% | |
Avg P/E ratio | x | 23.4 | -9.4 | -249.5% | |
P/CF ratio (eoy) | x | 19.5 | -9.5 | -205.3% | |
Price / Book Value ratio | x | 2.3 | 1.8 | 129.4% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 45,368 | 1,561 | 2,906.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 3,909 | 151 | 2,581.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 17,838 | 446 | 3,998.6% | |
Other income | Rs m | 512 | 11 | 4,833.8% | |
Total revenues | Rs m | 18,350 | 457 | 4,018.0% | |
Gross profit | Rs m | 2,496 | -161 | -1,553.3% | |
Depreciation | Rs m | 389 | 2 | 19,469.5% | |
Interest | Rs m | 41 | 71 | 57.9% | |
Profit before tax | Rs m | 2,578 | -223 | -1,157.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 640 | -56 | -1,136.5% | |
Profit after tax | Rs m | 1,938 | -166 | -1,164.9% | |
Gross profit margin | % | 14.0 | -36.0 | -38.8% | |
Effective tax rate | % | 24.8 | 25.3 | 98.2% | |
Net profit margin | % | 10.9 | -37.3 | -29.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 14,431 | 358 | 4,030.5% | |
Current liabilities | Rs m | 7,296 | 940 | 775.8% | |
Net working cap to sales | % | 40.0 | -130.6 | -30.6% | |
Current ratio | x | 2.0 | 0.4 | 519.5% | |
Inventory Days | Days | 265 | 85 | 310.1% | |
Debtors Days | Days | 251 | 1,135 | 22.1% | |
Net fixed assets | Rs m | 17,347 | 1,262 | 1,374.7% | |
Share capital | Rs m | 166 | 432 | 38.4% | |
"Free" reserves | Rs m | 19,655 | 450 | 4,364.4% | |
Net worth | Rs m | 19,820 | 882 | 2,246.9% | |
Long term debt | Rs m | 6 | 0 | - | |
Total assets | Rs m | 31,796 | 1,620 | 1,962.8% | |
Interest coverage | x | 64.1 | -2.2 | -2,974.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.3 | 203.7% | |
Return on assets | % | 6.2 | -5.9 | -105.3% | |
Return on equity | % | 9.8 | -18.9 | -51.8% | |
Return on capital | % | 13.2 | -17.2 | -76.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 8.5 | 14.5 | 58.5% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,509 | 65 | 2,339.5% | |
Fx inflow | Rs m | 3,259 | 0 | - | |
Fx outflow | Rs m | 1,509 | 65 | 2,339.5% | |
Net fx | Rs m | 1,749 | -65 | -2,711.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,549 | 109 | 1,422.3% | |
From Investments | Rs m | 111 | 5 | 2,410.2% | |
From Financial Activity | Rs m | -1,800 | -147 | 1,223.2% | |
Net Cashflow | Rs m | -138 | -34 | 412.2% |
Indian Promoters | % | 69.7 | 59.3 | 117.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 9.6 | 0.0 | - | |
FIIs | % | 2.7 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 30.3 | 40.8 | 74.5% | |
Shareholders | 52,377 | 35,313 | 148.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare FDC With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | FDC | BH.IMMUN&BIO | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.23% | -2.69% | 0.45% |
1-Month | 8.18% | 6.17% | 2.55% |
1-Year | 55.22% | 31.70% | 56.14% |
3-Year CAGR | 14.08% | -9.09% | 15.22% |
5-Year CAGR | 23.45% | 32.05% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the FDC share price and the BH.IMMUN&BIO share price.
Moving on to shareholding structures...
The promoters of FDC hold a 69.7% stake in the company. In case of BH.IMMUN&BIO the stake stands at 59.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of FDC and the shareholding pattern of BH.IMMUN&BIO.
Finally, a word on dividends...
In the most recent financial year, FDC paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.
BH.IMMUN&BIO paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of FDC, and the dividend history of BH.IMMUN&BIO.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.